Treace Medical Concepts (TMCI) CCO receives 150,000 RSU grant

Rhea-AI Filing Summary

Treace Medical Concepts, Inc. reported an equity award to its Chief Commercial Officer, Gaetano Guglielmino. On January 22, 2026, he was granted 150,000 restricted stock units (RSUs) of common stock at a price of $0 per share. Each RSU converts into one share of common stock as it vests. The RSUs vest in four equal annual installments, starting on January 22, 2027 and ending on January 22, 2030, conditioned on his continued service with the company. Following this grant, he beneficially owns 490,901 shares of common stock, including 422,250 RSUs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Guglielmino Gaetano

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	150,000	$0.00	--

Holdings After Transaction: Common Stock — 490,901 shares (Direct)

Footnotes (1)

1. Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date. Includes 422,250 restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guglielmino Gaetano

(Last) (First) (Middle)

100 PALMETTO PARK PLACE

(Street)

PONTE VEDRA FL 32081

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/22/2026		A		150,000(1)	A	$0	490,901(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs vest in equal annual installments over 4 years, with the first installment vesting on January 22, 2027 and the last installment vesting on January 22, 2030; subject to Reporting Person's providing continued service to Issuer through each vesting date.

2. Includes 422,250 restricted stock units.

	/s/ Lisa Taylor as Attorney-in-fact for Gaetano Guglielmino	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did TMCI report for Gaetano Guglielmino?

Treace Medical Concepts, Inc. reported that Chief Commercial Officer Gaetano Guglielmino received an award of 150,000 restricted stock units (RSUs) of common stock on January 22, 2026.

What are the vesting terms of the 150,000 RSUs granted by TMCI?

The 150,000 RSUs vest in four equal annual installments, with the first installment on January 22, 2027 and the final installment on January 22, 2030, subject to his continued service with the company.

Does each RSU granted to the TMCI CCO equal one share of common stock?

Yes. Each restricted stock unit entitles the holder to receive one share of Treace Medical Concepts common stock upon vesting.

What price was paid for the TMCI RSU award to the Chief Commercial Officer?

The 150,000 RSUs were reported with a transaction price of $0 per share, indicating they were granted as equity compensation rather than purchased for cash.

How many Treace Medical Concepts shares does the CCO beneficially own after this grant?

After the grant, Gaetano Guglielmino beneficially owns 490,901 shares of Treace Medical Concepts common stock, which includes 422,250 RSUs.

Is this TMCI insider transaction a direct or indirect holding?

The filing shows the Chief Commercial Officer’s holdings, including the new RSU grant, as direct beneficial ownership.